CaBP1 and CaBP2 are important for maintaining hearing by supporting continuous calcium currents and nerve signaling in the ear.
January 2024 in “Fitoterapia” Vitamin D3 is crucial for immune and bone health, with most consumers being women who follow doctor advice.
December 2023 in “Journal of Medicinal Chemistry” A new topical treatment for hair loss shows strong hair growth effects with low toxicity.
November 2023 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively maintains hair regrowth in alopecia areata patients.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Ritlecitinib significantly improves scalp hair regrowth in alopecia areata patients over time.
September 2022 in “Journal of The American Academy of Dermatology” Baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata.
January 2022 in “Maxillofacial Plastic and Reconstructive Surgery” The book is a detailed guide on facial cosmetic surgery techniques and advancements, useful for both trainees and specialists.
May 2021 in “Journal of the Endocrine Society” A woman's hair loss and other symptoms were due to a rare hormone deficiency treatable with steroids.
May 2017 in “Journal of The American Academy of Dermatology” The treatment increased hair follicle counts and is potentially effective for male hair loss without serious side effects.
July 2015 in “Hair transplant forum international” The 2015 ISHRS workshop in Denver successfully improved training for hair restoration surgery assistants.
December 2010 in “SciVee”
March 1998 in “Hair transplant forum international” I'm sorry, but I can't provide a summary as no specific conclusion or information from the meeting is provided.
October 1993 in “The Journal of Clinical Pharmacology” April 2014 in “The FASEB Journal” Women with androgenetic alopecia often have other symptoms of high androgen levels, requiring further hormone testing.
9 citations
,
January 2017 in “Organic Process Research & Development” In 2017, a new method was created to efficiently produce a topical antiandrogen, a compound used to treat excess sebum and acne, with a high yield and purity.
354 citations
,
August 1991 in “Molecular Endocrinology” Human adrenals and gonads have a unique enzyme for steroid hormone production.
34 citations
,
January 1987 in “Dermatology” Topical minoxidil effectively and safely treats extensive alopecia areata but doesn't change its course.
29 citations
,
February 2019 in “Journal of Microbiology and Biotechnology” Silibinin may help hair growth and treat hair loss.
22 citations
,
September 2014 in “JAMA dermatology” Ichthyosis with confetti is a genetic skin disorder with consistent ectodermal malformations and various KRT10 gene mutations.
17 citations
,
September 2014 in “PLoS ONE” SK2 channels help control sensory signals in rat muscle spindles and hair follicles.
15 citations
,
April 2008 in “Steroids” The more lipophilic the progesterone derivative, the better it binds to androgen receptors and has antiandrogenic effects.
11 citations
,
July 2010 in “European Journal of Dermatology” The condition is linked to chromosome 12, but no mutations were found in the known genes.
4 citations
,
September 2025 in “Journal of the American Academy of Dermatology” 2 citations
,
August 2024 in “JID Innovations” AD-derived keratinocytes effectively mimic inflammation in atopic dermatitis.
1 citations
,
October 2025 in “International Journal of Dermatology” Ritlecitinib improves emotional well-being and activity levels in alopecia areata patients.
1 citations
,
July 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is effective and safe for long-term treatment of alopecia areata.
March 2026 in “American Journal of Clinical Dermatology” Ritlecitinib is effective and safe for long-term use in treating severe alopecia areata in people aged 12 and older.
February 2026 in “The Journal of Dermatology” Ritlecitinib effectively regrows scalp, eyebrow, and eyelash hair in Asians with alopecia areata and is safe.
September 2025 in “Journal of the American Academy of Dermatology” Deuruxolitinib improves anxiety and depression in severe alopecia areata patients.
January 2025 in “SKIN The Journal of Cutaneous Medicine” Some patients on Baricitinib for alopecia areata lost response, often linked to longer and more severe initial conditions.